Brief: Genprex Announces The Opening For Enrollment Of Its Phase 1/2 Acclaim-2 Clinical Trial Of Reqorsa Immunogene Therapy In Combination With Keytruda To Treat Non-Small Cell Lung Cancer
31/03/2022 13:25
March 31 (Reuters) - Genprex Inc GNPX.O :
* GENPREX ANNOUNCES THE OPENING FOR ENROLLMENT OF ITS PHASE
1/2
ACCLAIM-2 CLINICAL TRIAL OF REQORSA IMMUNOGENE THERAPY IN
COMBINATION WITH KEYTRUDA TO TREAT NON-SMALL CELL LUNG CANCER
Source text for Eikon: ID:nBwszpPva
Further company coverage: GNPX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Genprex
See all newsBrief: Genprex Announces Collaboration With Roche Diagnostics For Biomarker Assay Validation Studies
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Genprex Announces Ip Australia's Intent To Grant Patent For Reqorsa® Gene Therapy